Trial record 1 of 1 for:
INCA32459-101
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05577182 |
|
Recruitment Status :
Recruiting
First Posted : October 13, 2022
Last Update Posted : April 26, 2024
|
Sponsor:
Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD). Part 2 (dose expansion) will further evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of INCA 32459 at the recommended dose(s) for expansion in 2 tumor-specific cohorts.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Malignancies | Drug: INCA32459-101 | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 120 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Intervention Model Description: | Part 1 will be dose escalation using a statistical hybrid design to identify the RDE(s). Part 2 will be dose expansion portion which will administer the RDE(s) defined in Part 1 to participants in 2 tumor-specific cohorts. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies |
| Actual Study Start Date : | November 14, 2022 |
| Estimated Primary Completion Date : | April 10, 2026 |
| Estimated Study Completion Date : | April 10, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1: Dose Escalation
INCA32459 will be administered at a protocol defined starting regimen intravenously. Subsequent dose regimens will be determined during study conduct.
|
Drug: INCA32459-101
solution for infusion |
|
Experimental: Part 2: Dose Expansion Cohort Disease Group 1
INCA32459 will be administered at the recommended dose or doses for expansion (RDE[s]) for unresectable or metastatic melanoma.
|
Drug: INCA32459-101
solution for infusion |
|
Experimental: Part 2: Dose Expansion Cohort Disease Group 2
INCA32459 will be administered at the recommended dose or doses for expansion (RDE[s]) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) that is PD-L1 positive.
|
Drug: INCA32459-101
solution for infusion |
Primary Outcome Measures :
- Part 1: Occurrence of Dose Limiting Toxicities (DLTs) [ Time Frame: Up to approximately 12 months ]Toxicities occurring during Part 1 will define tolerability. DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 12 months ]TEAE is any Adverse Event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.
- Number of Participants with Dose Interruptions due to TEAE [ Time Frame: Up to approximately 12 months ]Dose interruptions will occur according to protocol guidelines.
- Number of Participants discontinue study due to TEAE [ Time Frame: Up to approximately 12 months ]TEAE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Secondary Outcome Measures :
- Objective Response Rate (ORR) [ Time Frame: Up to 12 months ]Defined as having Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or Lugano criteria (B-cell lymphomas only).
- Disease Control Response (DCR) [ Time Frame: Up to 12 months ]Defined as having CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1. or Lugano criteria (B-cell lymphomas only).
- Duration of Response (DOR) [ Time Frame: Up to 12 months ]Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or Lugano criteria (B-cell lymphomas only) or death due to any cause if occurring sooner than progression.
- PK parameters: Cmax [ Time Frame: Up to 24 months ]Defined as the maximum (peak) plasma drug concentration
- PK parameters: tmax [ Time Frame: Up to 24 months ]Defined as the time to reach maximum (peak) plasma concentration following drug administration
- PK parameters: Cmin [ Time Frame: Up to 24 months ]Defined as concentration at the end of the dosing interval
- PK Parameters: AUC [ Time Frame: Up to 24 months ]Defined as the area under the plasma concentration-time curve
- PK Parameters: CL [ Time Frame: Up to 24 months ]Defined as the apparent total body clearance of the drug from plasma
- PK Parameters: Vz [ Time Frame: Up to 24 months ]Defined as apparent volume of distribution during terminal phase
- PK Parameters: t1/2 [ Time Frame: Up to 24 months ]Defined as Elimination half-life (to be used in one-or noncompartmental model)
- Receptor Occupancy [ Time Frame: Up to 24 months ]Defined as PD-1 receptor occupancy in peripheral blood samples.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Histologically or cytologically confirmed advanced malignancies as follows:
- Part 1 only: Participants with the select advanced malignancies as specified in the protocol.
-
Part 2 only:
- Cohort 1 only: Participants with Stage III (unresectable) or Stage IV (metastatic) melanoma that is considered nonamenable to curative treatments or procedures.
- Cohort 2 only: Participants with histologically or cytologically confirmed recurrent/metastatic SCCHN that is PD-L1 positive (CPS ≥ 1) which is not amenable to local therapy with curative intent.
-
Participants must have experienced disease progression after treatment with standard therapies, or are intolerant to or ineligible for standard treatment:
- Part 1: All available standard therapies, including anti-PD-(L)1 and platinum-based therapy, if applicable, that are known to confer clinical benefit. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance.
- Part 2: Available standard therapies, including anti-PD-(L)1 and platinum-based therapy, if applicable, that are known to confer clinical benefit. Prior anti-PD-(L)1 therapy should not have been discontinued because of intolerance. Part 2 participants may have received up to 2 prior systemic therapies in the a advanced/metastatic setting.
- ECOG performance status of 0 or 1
- Part 2 only: Measurable disease according to RECIST v1.1.
- Part 2 only: Willingness to undergo a fresh tumor biopsy at screening (core or excisional).
- Part 2 only: Willingness to undergo a fresh tumor biopsy at screening and on-treatment in selected participant.
- Willingness to avoid pregnancy or fathering children
Exclusion Criteria:
- Prior treatment with any LAG-3- or MHC Class II-directed therapy for current malignancy, or any prior malignancy.
- Treatment with anticancer therapies or participation in another interventional clinical study within 28 days before the first administration of study treatment (this includes curative radiation to the thorax or systemic anticancer therapies).
- Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy (with exceptions specified in the protocol).
- Not recovered adequately from toxicities and/or complications from surgical intervention before starting study treatment.
- Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy in the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment.
- Any known additional malignancy that is progressing or requires active treatment; history of other malignancy within 3 years of the first dose of study treatment (with exceptions specified in the protocol).
- Evidence of interstitial lung disease or history of interstitial lung disease, or active, noninfectious pneumonitis.
- Active autoimmune disease requiring systemic immunosuppression with corticosteroids (> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment.
- Untreated brain or CNS metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases).
- Chronic treatment with systemic steroids (> 10 mg/day of prednisone or equivalent).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05577182
Contacts
| Contact: Incyte Corporation Call Center (US) | 1.855.463.3463 | medinfo@incyte.com | |
| Contact: Incyte Corporation Call Center (ex-US) | +800 00027423 | eumedinfo@incyte.com |
Locations
Show 24 study locations
Sponsors and Collaborators
Incyte Corporation
| Responsible Party: | Incyte Corporation |
| ClinicalTrials.gov Identifier: | NCT05577182 |
| Other Study ID Numbers: |
INCA 32459-101 |
| First Posted: | October 13, 2022 Key Record Dates |
| Last Update Posted: | April 26, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Incyte Corporation:
|
LAG-3 bispecific antibody melanoma squamous cell carcinoma of the head and neck (SCCHN) |
Additional relevant MeSH terms:
|
Neoplasms |